LARRY LIPSHULTZ to Microbial Collagenase
This is a "connection" page, showing publications LARRY LIPSHULTZ has written about Microbial Collagenase.
Connection Strength
1.184
-
Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie's disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies. BJU Int. 2015 Oct; 116(4):650-6.
Score: 0.444
-
Long-Term Satisfaction With Collagenase Clostridium Histolyticum for Peyronie's Disease: Clinical Predictors and Side Effect Profile. Urol Pract. 2025 01; 12(1):168-175.
Score: 0.211
-
Clinical Significance of Shortened Penile Length and Alterations in Penile Length Following Treatment for Peyronie's Disease. Sex Med Rev. 2022 07; 10(3):409-420.
Score: 0.182
-
Long-Term Safety and Curvature Deformity Characterization in Patients Previously Treated with Collagenase clostridium Histolyticum for Peyronie's Disease. J Urol. 2020 06; 203(6):1191-1197.
Score: 0.153
-
Minimally invasive treatment of Peyronie's disease: evidence-based progress. BJU Int. 2014 Jul; 114(1):16-24.
Score: 0.104
-
Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J Urol. 2012 Jun; 187(6):2268-74.
Score: 0.090